Tobias Ruck
Tobias Ruck is an expert in Neurology at BG University Hospital Bergmannsheil Bochum (Germany). As of October 2026, ScienceLeadR ranks Tobias Ruck in the top 1% of experts worldwide for Autoimmune Diseases, and in the top 1% of experts in Germany for Myositis. Tobias Ruck has authored 342 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 4 of them ongoing. SLR score: 1,161 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Biochemistry - Immunology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 342
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Serum circulating cell-free messenger RNA profile response to risdiplam treatment in adult patients with late-onset spinal muscular atrophy. PMID 42798856 — muscular atrophy, cells, genes, serum, atrophy, rna, messenger, biomarkers, therapeutics, muscular atrophy, spinal, liquid biopsy, spine | Brain Commun | 2026 | 0 |
| Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. PMID 42717567 — complement c5, complement inactivating agents, immunotherapy, therapeutics, nervous system diseases, neurologists, myasthenia gravis | Eur J Neurol | 2026 | 0 |
| Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study. PMID 42629559 — cells, sclerosis, multiple sclerosis, serum, interleukin-6, cohort studies, biomarkers, therapeutics, nervous system diseases, b-lymphocytes | BMC Neurol | 2026 | 0 |
| Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta-Analysis, and Meta-Regression. PMID 42590908 — treatment outcome, activities of daily living, complement inactivating agents, therapeutics, nervous system diseases, myasthenia gravis | Eur J Neurol | 2026 | 0 |
| Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. PMID 42507440 — injections, activities of daily living, safety, therapeutics, complement activation, nervous system diseases, myasthenia gravis | JAMA Neurol | 2026 | 0 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to assess the long term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy 2022-502851-79-00 — muscular diseases, safety, aged, myositis | Phase 3 | Active not recruiting | 2023 |
| Understanding the Durable Effect Concept of B cell Modulating Therapies NCT06586177 — cells, sclerosis, multiple sclerosis, tomography, optical coherence, therapeutics, b-lymphocytes, multiple sclerosis, relapsing-remitting | N/A | Recruiting | 2021 |
| A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7 MUSK AGRN or LRP4 NCT06078553 — natural history, myasthenic syndromes, congenital, history, mutation | N/A | Recruiting | 2024 |
| Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis NCT05556096 — complement c5, safety, receptors, cholinergic, syringes, complement system proteins, acetylcholine, myasthenia gravis | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map